Anti-IL-8 antibody [EPR26511-74]
- 20ul selling size
- RabMAb
- Recombinant
- KO Validated
- What is this?
Be the first to review this product! Submit a review
|
(11 Publications)
Rabbit Recombinant Monoclonal IL-8 antibody. Suitable for ICC/IF, IP, WB, Flow Cyt (Intra) and reacts with Human samples. Cited in 11 publications.
View Alternative Names
IL8, CXCL8, Interleukin-8, IL-8, C-X-C motif chemokine 8, Chemokine (C-X-C motif) ligand 8, Emoctakin, Granulocyte chemotactic protein 1, Monocyte-derived neutrophil chemotactic factor, Monocyte-derived neutrophil-activating peptide, Neutrophil-activating protein 1, Protein 3-10C, T-cell chemotactic factor, GCP-1, MDNCF, MONAP, NAP-1
- Flow Cyt (Intra)
Supplier Data
Flow Cytometry (Intracellular) - Anti-IL-8 antibody [EPR26511-74] (AB289967)
Intracellular flow cytometric analysis of 2% paraformaldehyde fixed, 0.1% saponin permeabilised human peripheral blood mononuclear cell (PBMC) treated with 1μg/ml Lipopolysaccharide (LPS) for 22 hours, then add 3uM Monensin for another 2h (Right). Untreated control (Left).
Primary antibody : ab289967, at 1/500 dilution.
Secondary antibody : Goat Anti-Rabbit IgG (Alexa Fluor® 488, ab150081) at 1/2000 dilution.
Scatter image shows specific IL-8 expression in LPS induced monocyte population.
- ICC/IF
Supplier Data
Immunocytochemistry/ Immunofluorescence - Anti-IL-8 antibody [EPR26511-74] (AB289967)
Immunofluorescent analysis of 4% Paraformaldehyde-fixed, 0.1% TritonX-100 permeabilized U-937 cells labelling IL-8 with ab289967 at 1/100 (5.87 μg/ml) dilution, followed by ab150081 Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) preadsorbed antibody at 1/1000 (2 μg/mL) dilution (Green). Confocal image showing cytoplasmic staining is observed in U-937 cells treated with TPA (100 ng/mL) for 24 h, then LPS (5 μg/mL) for 7 h with Brefeldin A (300 ng/mL) for the last 3 h. ab195889 Anti-alpha Tubulin mouse monoclonal antibody - Microtubule Marker (Alexa Fluor® 594) was used to counterstain tubulin at 1/200 (2.5μg/ml) dilution (Red). The Nuclear counterstain was DAPI (Blue).
Secondary antibody only control : Secondary antibody is ab150081 Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) preadsorbed at 1/1000 (2 μg/mL) dilution.
- Flow Cyt (Intra)
Supplier Data
Flow Cytometry (Intracellular) - Anti-IL-8 antibody [EPR26511-74] (AB289967)
Intracellular flow cytometric analysis of 4% paraformaldehyde fixed 90% methanol permeabilized U-937 (Human histiocytic lymphoma monocyte) treated with 100ng/ml TPA for 24 hours, then 5μg/ml LPS for 4 hours, and add 300ng/ml BFA for another 3h (Red) / Untreated control (Green) cells labelling IL-8 with ab289967 at 1/500 dilution (0.1μg) compared with a Rabbit monoclonal IgG (ab172730) (Black) isotype control and an unlabelled control (cells without incubation with primary antibody and secondary antibody) (Blue). A Goat Anti-Rabbit IgG (Alexa Fluor® 488, ab150081) at 1/2000 dilution was used as the secondary antibody.
- IP
Supplier Data
Immunoprecipitation - Anti-IL-8 antibody [EPR26511-74] (AB289967)
IL-8 was immunoprecipitated from U937 (human histiocytic lymphoma monocyte) treated with 100ng/ml TPA for 24h then treated with 5 μg/ml LPS for 4h, and add 300 ng/ml BFA for another 3h, whole cell lysate with ab289967 at 1/30 dilution (2 μg in 0.35mg lysates). Western blot was performed on the immunoprecipitate using ab289967 at 1/1000 dilution. VeriBlot for IP secondary antibody(HRP)(ab131366) was used at 1/5000 dilution.
Lane 1 : U937 (human histiocytic lymphoma monocyte) treated with 100 ng/ml TPA for 24h then treated with 5 μg/ml LPS for 4h, and add 300 ng/ml BFA for another 3h, whole cell lysate 10 μg
Lane 2 : ab289967 IP in U937 treated with 100 ng/ml TPA for 24h then treated with 5 μg/ml LPS for 4h, and add 300 ng/ml BFA for another 3h, whole cell lysate
Lane 3 : Rabbit monoclonal IgG (ab172730) instead of ab289967 in U937 treated with 100 ng/ml TPA for 24h then treated with 5 μg/ml LPS for 4h, and add 300 ng/ml BFA for another 3h, whole cell lysate
Blocking and dilution buffer and concentration : 5% NFDM/TBST.
Exposure time : 50 seconds
All lanes:
Immunoprecipitation - Anti-IL-8 antibody [EPR26511-74] (ab289967)
Predicted band size: 11 kDa
false
- WB
Supplier Data
Western blot - Anti-IL-8 antibody [EPR26511-74] (AB289967)
Blocking buffer and concentration was Intercept® (TBS) Blocking Buffer diluted with an equal volume of 0.1% TBS.
Diluting buffer was Intercept® (TBS) Blocking Buffer diluted with an equal volume of 0.1% TBST.
Lysates/proteins at 20 μg per lane.
Performed under reducing conditions.
False colour image of Western blot : Anti-IL-8 antibody [EPR26511-74] (ab289967) staining at 1/1000 dilution, shown in green; Mouse anti-GAPDH antibody [6C5] (ab8245) loading control staining at 1/20000 dilution, shown in red.
In Western blot, ab289967 was shown to bind specifically to IL-8. A band was observed at 11 kDa in wild-type PC-3 cell lysates with no signal observed at this size in CXCL8 knockout cell lysates. To generate this image, wild-type and CXCL8 knockout PC-3 cell lysates were analyzed. First, samples were run on an SDS-PAGE gel then transferred onto an immobilon-FL PVDF membrane. Membranes were blocked in Intercept® (TBS) Blocking Buffer diluted with an equal volume of 0.1% TBS before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) at 1/10000 dilution.
All lanes:
Western blot - Anti-IL-8 antibody [EPR26511-74] (ab289967) at 1/1000 dilution
Lane 1:
Wild-type PC-3 (human prostate adenocarcinoma epithelial cell) whole cell lysate at 20 µg
Lane 2:
Wild-type PC-3 treated with 2μg/ml LPS for 5h, then treated with 5μg/ml Brefeldin A for 5h, whole cell lysate at 20 µg
Lane 3:
CXCL8 knockout PC-3 whole cell lysate at 20 µg
Lane 4:
CXCL8 knockout PC-3 treated with 2μg/ml LPS for 5h, then treated with 5μg/ml Brefeldin A for 5h, whole cell lysate at 20 µg
Secondary
Lanes 1 - 4:
Western blot - Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (<a href='/en-us/products/secondary-antibodies/goat-mouse-igg-h-l-irdye-680rd-preadsorbed-ab216776'>ab216776</a>) at 1/10000 dilution
Lanes 1 - 4:
Western blot - Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-irdye-800cw-preadsorbed-ab216773'>ab216773</a>) at 1/10000 dilution
Predicted band size: 11 kDa
Observed band size: 11 kDa
false
- WB
Unknown
Western blot - Anti-IL-8 antibody [EPR26511-74] (AB289967)
Blocking and diluting buffer and concentration was 5% NFDM/TBST.
All lanes:
Western blot - Anti-IL-8 antibody [EPR26511-74] (ab289967) at 1/1000 dilution
Lane 1:
Untreated U-937 (human histiocytic lymphoma monocyte) whole cell lysate at 20 µg
Lane 2:
U-937 treated with TPA (100ng/mL) for 24 h, then treated with LPS (5 µg/mL) for 7 h with Brefeldin A (300 ng/mL) for the last 3 h, whole cell lysate at 20 µg
Lane 3:
Untreated U-87 MG (human glioblastoma-astrocytoma epithelial cell) whole cell lysate at 20 µg
Lane 4:
U-87 MG treated with 1μM Thapsigargin for 24h, whole cell lysate at 20 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution
Predicted band size: 11 kDa
Observed band size: 11 kDa
false
Exposure time: 70s
Related conjugates and formulations (1)
-
Anti-IL-8 antibody [EPR26511-74] - BSA and Azide free
Reactivity data
Product details
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage duration
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
IL-8 functions as a chemoattractant for neutrophils and lymphocytes facilitating their movement towards the site of infection or injury. It does not form part of a larger protein complex but operates individually to enhance immune cell migration. IL-8 possesses unique binding motifs allowing it to interact with specific receptors namely CXCR1 and CXCR2 on target cells. This binding triggers cellular responses leading to effective immune surveillance and response to inflammatory stimuli.
Pathways
IL-8 operates within important inflammatory and immune response pathways. It forms a part of the NF-κB signaling cascade which activates in response to stress signals promoting the expression of other inflammatory mediators. Additionally it engages in the mitogen-activated protein kinase (MAPK) pathway influencing cellular responses such as proliferation and differentiation. The interaction of IL-8 with these pathways highlights its role in modulating immune responses and highlights its interaction with other proteins such as TNF-α and IL-1β.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (11)
Recent publications for all applications. Explore the full list and refine your search
Journal of translational medicine 23:1056 PubMed41053808
2025
Applications
Unspecified application
Species
Unspecified reactive species
International dental journal 75:1649-1661 PubMed40138999
2025
Applications
Unspecified application
Species
Unspecified reactive species
Clinical & experimental metastasis 42:12 PubMed39856383
2025
Applications
Unspecified application
Species
Unspecified reactive species
Biomedicines 12: PubMed39335502
2024
Applications
Unspecified application
Species
Unspecified reactive species
Frontiers in oncology 14:1412660 PubMed39193386
2024
Applications
Unspecified application
Species
Unspecified reactive species
iScience 27:109861 PubMed38799570
2024
Applications
Unspecified application
Species
Unspecified reactive species
Cellular and molecular biology (Noisy-le-Grand, France) 69:186-192 PubMed38279450
2024
Applications
Unspecified application
Species
Unspecified reactive species
iScience 26:107894 PubMed37766998
2023
Applications
Unspecified application
Species
Unspecified reactive species
Critical reviews in eukaryotic gene expression 33:1-12 PubMed37183942
2023
Applications
Unspecified application
Species
Unspecified reactive species
Experimental and therapeutic medicine 25:75 PubMed36684653
2023
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com